Valued at a market cap of $217 billion, Abbott Laboratories (ABT) is a healthcare company that develops, manufactures, and sells a broad range of medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals. The North Chicago, Illinois-based company is expected to announce its fiscal Q4 earnings for 2025 in the near future. Ahead of this event, analysts expect this healthcare company to report a profit of $1.50 per share, up 11.9% from $1.34 per share in the year-ago quarter. The ...

Market Performance - On December 24, 2025, U.S. stocks reached record highs, with the S&P 500 closing at 6,932.05, up 22.26 points (0.3%), the Dow Jones Industrial Average at 48,731.16, up 288.75 points (0.6%), and the Nasdaq Composite at 23,613.31, up 51.46 points (0.2%) [2] - This performance marked the third consecutive year of double-digit percentage gains, driven by optimism surrounding artificial intelligence, anticipated interest rate cuts, and sustained economic growth despite recession fears [2] Economic Insights - The U.S. economy expanded at a robust annual pace of 4.3% in Q3 2025, exceeding economists' expectations, supported by a healthy labor market and falling unemployment claims [4] - Consumer confidence has dipped to its lowest level since April due to concerns over high prices, while Personal Consumption Expenditures (PCE) inflation increased to 2.8%, presenting challenges for the Federal Reserve [4] Corporate News - Novo Nordisk A/S saw a 7.3% increase in shares following FDA approval of its GLP-1 pill for treating obesity [6] - Huntington Ingalls Industries Inc. experienced a 0.3% rise in stock due to U.S. government plans for a new class of battleships [10] - ServiceNow Inc. shares fell 1.5% after announcing the acquisition of cybersecurity startup Armis for $7.75 billion [10] - ZIM Integrated Shipping Services Ltd. surged 5.8% as its board evaluates potential acquisitions [10] - Marvell Technology Inc. gained 3.4% driven by strong performance in AI [10] - Nvidia's stock rose 3% on December 24, contributing significantly to market gains [10] - DENSO CORPORATION announced a joint development agreement with MediaTek Inc. to advance next-generation automotive system-on-chips [10] Upcoming Events - The minutes from the December Federal Open Market Committee meeting will be released on December 30, 2025, providing insights into the Fed's monetary policy outlook [5] - Key Chinese economic data, including PMI figures, are expected on December 31, 2025, along with global PMI surveys and crucial U.S. non-farm payroll data in early January 2026 [5]

In this article, we will look at the 15 Best Affordable Stocks to Buy According to Analysts.On December 24, Kevin Mahn, President and CIO of Hennion & Walsh Asset Management, appeared on a CNBC Television interview to discuss his market outlook for 2026. He noted that 2025 has been a phenomenal year, with 41 record high closes for the S&P 500, resulting in a total return of around 18%. Moreover, the market also reached a 3-year anniversary of the bull market. Mahn believes that 2026 is going to be another b ...

Core Insights - Eli Lilly has emerged as a significant growth player in the pharmaceutical industry, particularly due to its leadership in the weight-loss drug market, delivering double-digit revenue growth [5][2] - The company's weight loss portfolio generated over $10 billion in revenue in the latest quarter, highlighting its strong market position [5][6] - Analysts predict that the weight loss drug market could approach $100 billion by the end of the decade, positioning Eli Lilly to benefit significantly from this growth [8] Company Overview - Eli Lilly's key products include tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, which have been prescribed for weight loss since 2022 [6][5] - The company has a market capitalization of $1.0 trillion and a gross margin of 83.03%, indicating strong financial health [7] - Demand for Lilly's drugs has been high, often surpassing supply, and the company is actively expanding its weight loss portfolio with new candidates like orforglipron and retatrutide [7][6] Market Potential - The weight loss drug market is expected to grow significantly, with analysts forecasting it to reach nearly $100 billion by the end of the decade, which presents a substantial opportunity for Eli Lilly [8] - The company's strategic focus on expanding its product offerings in this lucrative market could enhance its growth trajectory and revenue potential [7][8] Investment Strategy - Including Eli Lilly in a diversified portfolio of quality stocks is suggested as a strategy to potentially achieve significant retirement savings, with the company being a strong candidate for long-term investment [9]

九州通公告，2025年12月25日，子公司北京京丰制药集团有限公司下属公司汇禹远和（海南）药业有限 公司收到国家药品监督管理局核准签发的盐酸异丙嗪注射液《药品注册证书》。盐酸异丙嗪注射液为抗 组胺药，适用于皮肤粘膜过敏、晕动病、麻醉和手术前后的辅助治疗、防治放射病性或药源性恶心、呕 吐。截至本公告日，汇禹远和针对该药品已投入的研发费用约人民币467万元（未经审计）。 ...

Core Insights - The Zacks Equity Research team has highlighted several stocks, including AbbVie Inc., The Coca-Cola Co., Chevron Corp., ImmuCell Corp., and Precipio, Inc., in their Analyst Blog [1][2]. AbbVie Inc. (ABBV) - AbbVie has outperformed the Zacks Large Cap Pharmaceuticals industry over the past year, with a share price increase of +31.6% compared to the industry’s +19.5% [4]. - The company has successfully managed the loss of exclusivity for Humira by launching new immunology drugs, Skyrizi and Rinvoq, which are performing well and expected to support revenue growth [4][5]. - AbbVie is returning to robust revenue growth in 2025, following the U.S. Humira loss of exclusivity, and has been actively acquiring companies to enhance its early-stage pipeline [5]. The Coca-Cola Co. (KO) - Coca-Cola's shares have outperformed the Zacks Beverages - Soft Drinks industry over the past year, with a gain of +14.5% compared to +10.5% for the industry [6]. - The company's performance is attributed to solid organic revenue growth, effective pricing strategies, and gains in global market share within the non-alcoholic ready-to-drink category [6][7]. - Ongoing innovation and digital transformation efforts are enhancing Coca-Cola's competitive edge, although the company faces challenges such as soft volumes in key regions and currency headwinds [7][8]. Chevron Corp. (CVX) - Chevron's shares have increased by +9.5% over the past year, while the Zacks Oil and Gas - Integrated - International industry has gained +16% [9]. - The acquisition of Hess has significantly improved Chevron's growth outlook by adding high-quality assets in regions like Guyana and the Gulf of Mexico [9]. - The Permian Basin remains a key asset for Chevron, driving consistent growth, although challenges such as lower crude realizations and regulatory issues in California temper optimism [10]. ImmuCell Corp. (ICCC) - ImmuCell has outperformed the Zacks Medical - Products industry with a share price increase of +26.3% compared to +1% for the industry [11]. - The company’s First Defense franchise leads the market in calf scours prevention, with Tri-Shield accounting for 70% of volume and a 48% market share [11][12]. - ImmuCell has resolved operational bottlenecks, restoring capacity to $30 million in annual sales, with TTM revenues of $27.8 million, reflecting a 16% year-over-year increase [12][13]. Precipio, Inc. (PRPO) - Precipio's shares have surged by +361.2% over the past year, significantly outperforming the Zacks Medical Info Systems industry, which saw a decline of -1.3% [14]. - The company is moving towards self-funded growth, driven by its Pathology Services division, which is experiencing steady organic growth and rising margins [14][15]. - Precipio has improved profitability and cash flow, although it faces risks related to liquidity and regulatory uncertainties [15][16].

12月26日，和睦家医院向界面新闻回应日前女明星生产信息疑似被泄露一事， 称"无医疗纠纷或异议，我院没有医护人员参与泄露任何患 者隐私的行为"。 日前，网传聊天截图称，一女明星在和睦家生产，并提及孩子健康状况不佳、转院等细节信息。从截图判断信息来自医护人员。因而有声 音质疑和睦家工作人员泄露患者隐私，另有声音对和睦家产检结果产生疑问。 和睦家医疗成立近30年，以高端妇产科业务起家，后发展成综合型医院，现为国内知名高端私立医疗机构。其与公立医疗机构互为补充， 以服务体验、高值药械等吸引患者，成为不少名人、高收入家庭的选择。 来源：界面新闻 同仁堂致歉 罗永浩吐槽"宽带缩水"，上海电信回应 N # 啊 _ | ■ i 关注" 新华网财经 "视频号 更多财经资讯等你来看 往期推荐 ...

近日，盘龙药业在互动平台向投资者表示，公司积极布局大健康产品线上销售渠道，目前在京东商城 （盘龙专营店）、淘宝（盘龙大健康企业店）、微盟（盘龙大健康）、微信小程序（盘龙优选）、视频 号（陕西盘龙）、抖音（盘龙企业店）共六个平台均有销售。公司目前大健康产品主要分为生活日化 类、保健食品类、功能食品类、保健养生用品类、"械""妆""消"字号产品等系列板块，主要产品有盘龙 七牙膏、盘龙修护面膜、盘龙黄芪抗皱面霜、盘龙七洗发水、骨胶归珍片、破壁灵芝孢子粉、蒲公英菊 花决明子茶等系列产品。 公司将持续完善线上渠道建设，稳步落实相关产品规划，致力于让更多盘龙 健康产品服务终端消费者。2025年1至9月，盘龙药业实现营收8.41亿元，同比增长17.37%；实现归母净 利润0.90亿元，同比增长0.26%。 ...

Market Overview - U.S. financial markets are closed on December 25, 2025, for Christmas Day, with trading resuming on December 26, 2025 [1] - Major indexes reached new record highs on Christmas Eve, driven by optimism in the U.S. economy and the AI boom [1][2] Index Performance - On December 24, 2025, the S&P 500 rose 0.3% to close at 6,932.05, the Dow Jones increased by 0.6% to 48,731.16, and the Nasdaq Composite edged up 0.2% to 23,613.31 [2] - For the week, the S&P 500 gained 1.4%, the Dow 1.2%, and the Nasdaq 1.3% [3] - Year-to-date performance shows the S&P 500 up 17.8%, the Dow up 14.5%, and the Nasdaq up 22.3%, largely due to the AI supercycle and fiscal policy shifts [3] Corporate Movements - Dynavax Technologies shares surged after Sanofi announced plans to acquire the company [4] - Nike's stock rose 4.6% following news of Apple CEO Tim Cook purchasing nearly $3 million in Nike shares [4] - Nvidia shares fell 0.3% amid reports of halted testing for an Intel production process, despite a year-to-date increase of nearly 40% [4] - Novo Nordisk's stock climbed 7.3% after FDA approval of its GLP-1 pill for obesity treatment [4] - Huntington Ingalls Industries shares rose 0.3% due to U.S. government plans for new battleships [4] - ServiceNow experienced a 1.5% decline after announcing the acquisition of Armis for $7.75 billion [4] - ZIM Integrated Shipping Services surged 5.8% as its board evaluates potential acquisitions [4] - Marvell Technology Inc. gained 3.4% driven by strong AI sector performance [4] Economic Indicators - Unemployment claims fell last week, indicating a healthy labor market [4] - The U.S. economy grew at a faster-than-expected annual pace of 4.3% in Q3 [4] - PCE inflation data increased to 2.8%, while November CPI decreased to 2.7%, complicating the Federal Reserve's policy outlook [11] Upcoming Events - The markets will reopen on December 26, 2025, with no major economic reports scheduled for that day [5] - The "Santa Claus rally" period is currently underway, historically associated with positive market performance [6] - Key economic data, including the December Non-Farm Payrolls report and the Consumer Price Index, will be released in early 2026 [7]

The U.S. stock market observes a quiet Christmas Day on Thursday, December 25, 2025, with all major exchanges, including the New York Stock Exchange (NYSE) and Nasdaq, closed for the holiday. This pause follows a robust, holiday-shortened trading session on Wednesday, December 24, where major indexes continued their upward trajectory, reaching new record highs. Investors are now looking ahead to the reopening of markets on Friday, December 26, and the economic landscape that awaits in the final days of 2025 ...